You can search in free text – simply type the disease, drug, company name, or other detail into the Search bar below and click Apply
Displaying 472 of 472
Amicus Therapeutics
Expanded Access for ATB200/AT2221 for the Treatment of IOPD
Conditions: Pompe Disease Infantile-Onset
This is an expanded access program (EAP) for eligible participants designed to provideaccess to ATB200/AT2221.
Matrix Biomed, Inc.
A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer
Conditions: Prostate Cancer
A single patient compassionate use clinical trial for the use of MBM-02 (TEMPOL) for thetreatment of prostate cancer. The single patient will be exposed to orally administeredTEMPOL for up to 12 months at a maximum total daily dose of 800mg.